Home Newsfeeds UBS Maintains Sell on Moelis & Co, Lowers Price Target to $30

UBS Maintains Sell on Moelis & Co, Lowers Price Target to $30

UBS analyst Brennan Hawken maintains Moelis & Co (NYSE:MC) with a Sell and lowers the price target from $32 to $30.

byBenzinga Newsdesk

January 9, 2023

1 minute read

UBS analyst Brennan Hawken maintains Moelis & Co (NYSE:MC) with a Sell and lowers the price target from $32 to $30.

Analyst Ratings

Where G1 Therapeutics Stands With Analysts

By Benzinga Insights

June 26, 12:00 PM

Within the last quarter, G1 Therapeutics (NASDAQ:GTHX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

GTHX

What’s Going On With US Pharma Giant Bristol-Myers Squibb Stock Today?

By Vandana Singh

February 2, 10:48 AM

Bristol Myers Squibb reports Q4 revenues of $11.48 billion, up 1% YoY. Eliquis and Opdivo sales drive growth, offsetting Revlimid decline.

BMY

Rada Electronics Industri Q2 EPS $(0.09) Down From $0.20 YoY, Sales $23.06M Miss $29.13M Estimate

By Bill Haddad

August 17, 7:14 AM

Rada Electronics Industri (NASDAQ:RADA) reported quarterly losses of $(0.09) per share. This is a 145 percent decrease over earnings of $0.20 per share from the same period last year. The company reported quarterly

RADA

BMO Capital Maintains Outperform on Victoria’s Secret, Lowers Price Target to $45

By Benzinga Newsdesk

August 25, 7:44 AM

BMO Capital analyst Simeon Siegel maintains Victoria's Secret (NYSE:VSCO) with a Outperform and lowers the price target from $50 to $45.

VSCO

UBS Maintains Sell on Moelis & Co, Lowers Price Target to $30

Related Posts

Where G1 Therapeutics Stands With Analysts

What’s Going On With US Pharma Giant Bristol-Myers Squibb Stock Today?

Rada Electronics Industri Q2 EPS $(0.09) Down From $0.20 YoY, Sales $23.06M Miss $29.13M Estimate

BMO Capital Maintains Outperform on Victoria’s Secret, Lowers Price Target to $45